NEWPORT BEACH, Calif.–(BUSINESS WIRE)–$SRPT #CureDuchenne—CureDuchenne,
a nonprofit dedicated to funding research and improving patient care for
Duchenne muscular dystrophy, will host a webinar
with Sarepta Therapeutics, Inc. (NASDAQ: SRPT) on October 11 at 1 p.m.
ET/10 a.m. PT to provide the Duchenne community an overview of Sarepta’s
patient support program, SareptAssist.
The webinar will address patient referrals, consideration for starting
therapy, case management process and financial assistance programs. The
webinar will be presented by Dan Madden, Director of Patient Services,
Sarepta Therapeutics, and moderated by Dr. Mike Kelly, CureDuchenne’s
Chief Scientific Officer. To learn more, please visit www.SareptAssist.com.
Duchenne muscular dystrophy is a fatal genetic disease that causes
muscle degeneration and affects 1 in 3,500 boys. Boys with Duchenne are
usually diagnosed by age 5, lose their ability to walk by age 12 and
most don’t survive their mid-20s. CureDuchenne provided early funding
and support to Sarepta Therapeutics that contributed to the development
To register for the webinar on October 11, click here.
The call in number is (844) 337-8088 and the conference ID number is
CureDuchenne was founded in 2003 with a focus on saving the lives of
those with Duchenne muscular dystrophy, a disease that affects more than
300,000 children and young adults worldwide. With support from
CureDuchenne, nine research projects have advanced to human clinical
trials. CureDuchenne also brings physical therapy and standard of care
to local communities around the country through its CureDuchenne
Cares program. For more information, please visit CureDuchenne.org
and follow us on Facebook,
Karen Harley, 949-872-2552